(NASDAQ: BRTX) Biorestorative Therapies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.1%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.8%.
Biorestorative Therapies's earnings in 2025 is -$6,170,671.On average, 1 Wall Street analyst forecast BRTX's earnings for 2025 to be -$5,951,130, with the lowest BRTX earnings forecast at -$5,951,130, and the highest BRTX earnings forecast at -$5,951,130. On average, 1 Wall Street analyst forecast BRTX's earnings for 2026 to be -$5,743,533, with the lowest BRTX earnings forecast at -$5,743,533, and the highest BRTX earnings forecast at -$5,743,533.
In 2027, BRTX is forecast to generate $23,735,322 in earnings, with the lowest earnings forecast at $23,735,322 and the highest earnings forecast at $23,735,322.